Full Length Research Paper

DFT studies of nano anticancer on vinblastine and vincristine molecules

M. Mousavi¹, A.R. Ilkhani², Sh.Sharifi³, J.Mehrzad⁴, A.Eghdami⁴ and M.Monajjemi^{5*}

¹M.Sc student, Science and Research Branch, Islamic Azad University, Tehran, Iran.
 ²Department of Chemistry, Yazd Branch, Islamic Azad University, Yazd, Iran
 ³Ph.D Student, Yazd Branch, Islamic Azad University, Yazd, Iran
 ⁴Ph.D Student, Science and Research Branch, Islamic Azad University, Tehran, Iran.
 ⁵Department of Chemistry, Science and Research Branch, Islamic Azad University, Tehran, Iran.

Accepted 19 January, 2013

Medicinal chemistry depends on many other disciplines ranging from organic chemistry and pharmacology to computational chemistry. Typically, medicinal chemists use the most straightforward ways to prepare compounds. The validation of any design project comes from the biological testing. The investigation of vinblastine and vincristine have been studied by theoretical methods. It has been established the best structural and functional of vinblastine and vincristine. In this study, we have extracted information of vinblastine and vincristine with hybrid density functional theory (B3LYP,BLYP) and hartree-fock (HF) methods by different basis sets, and then total energy, band gap, dipole moment, NMR parameter of VCR and VLB have been studied. Also, the information gathered in this investigation from the atomic structure of tubulin involved dynamic instability of microtubules, gives additional help in determining crucial binding site for the activity of potent antimitotic drugs.

Key words: Hybrid density functional theory (B3LYP, BLYP) and hartree-fock (HF), vinblastine, vincristine, drug.

INTRODUCTION

Alkaloids are biologically effective molecules taken from natural sources (Sen and Maiti, 1994; Chen et al., 2005; Qin et al., 2006). The alkaloids began in the late 1950s. Since then, more than eighty alkaloids have been isolated from C. roseus. Alkaloids are known to have anti cancerous, antimicrobial, antihypertensive and multiple other biological activities (Blaskó and Cordell, 1990; Bölcskei, 2005). Vinblastine and vincristine are a vinca alkaloid obtained from the famous Madagascar Periwinkle plant, an evergreen plant known more formally as Catharanthus roseus (Sen and Maiti,1994; Chen et al., 2005; Qin et al., 2006). They are an anticancer drug used to treat certain kinds of cancer (Nakagawa et al., 2005).

Vinca alkaloids (vinblastine, vincristine, and more recently, vinorelbine) are antimitotic, anticancer agents that induce tubulin to form spiral polymers at physiological protein concentrations. Sedimentation velocity to investigate the effects of six vinca alkaloids on tubulin spiraling. Thermodynamic analysis of LnK_1K_2 data demonstrates large and positive ΔS values, indicating that tubulin spiral formation is entropically-driven (Lobert et al., 2006).

Quantitatively examined the Additivity of Dilantin and Vinblastine Inhibitory Effects on Microtubule Assembly1 (Lobert et al., 1999). The interaction of vinblastine with calf brain tubulin has been studied by velocity sedimentation, gel filtration, and fluorescence (Lee et al., 1975). Then discuss the Physiochemical Aspects of Tubulin- interacting Antimitotic Drugs (Correia and Lobert ,2001).The interactions of vinblastine with tubulin heterodimers and microtubules have been studied extensively, and in Vitro studies have shown that at low ionic strengths vinblastine induces spiral formation by a mechanism involving ligand-mediated plus ligandfacilitated isodesmic self-association (Lobert et al., 1996). Tryptic hydrolysis identifies a single fluorescent β-peptide coinciding with residues 175–213 (Rai and Wolff, 1996).

Vincristine (VCR) a natural constituent of C.roseus which is produced in practice semisynthetically from VLB, is used mainly for acute lymphoblastic leukaemia and non-Hodgkin's lymphomas as well asother neoplastic

^{*}Corresponding Author: E-mail: m_monajjemi@yahoo.com

disorders like Wilms' tumor, neuroblastoma, Kaposi sarcoma and rhabdomyosarcoma (Pearce,1990 ;Kuehne and Markó , 1990;Va et al.,2010; Sasaki et al.,

2010). Vinblastine is an anti-metabolic agent. It effects on the metaphase stage of meiosis. Vincristine is an antimetabolic agent, too but it effects on the metaphase stage of mitosis (Smith,1997; Peters et al., 2000). There are several differences between meiosis and mitosis (Eric Hall, 2006). But in both case, in metaphase stage, chromosomes are placed in middle of Cell nucleus then

microtubules attached to them very hardly and are ready chromosomes to divide the (Mitchison and Poleward, 1989; Mitchison and Kirschner, 1984; Margolis Wilson, 1998; Rodionov et al., 1999; Rudner and and Murray, 1996). This doesn't happen if we use of vinblastine or vincristine because these two factors are binding to the microtubule and make them loose so the cell division stops at this stage and the cancer cells will not grow (Vale, 2003; Howard and Hyman, 2007; Jordan and Leslie, 2004).

The most of works in related to these molecules were experimentally that has been based on its performance on DNA and get evidence of their effects (Howard and Hyman, 2007; Jordan and Leslie, 2004; Jordan and Wilson, 1999).In view of their structural and biological similarities it is of considerable interest that in their use as anticancer agents VLB and VCR differ markedly in their spectra of oncolytic activity, the dosages which are tolerated and the symptoms of toxicity they elicit. VLB, for example, is one of the more useful drugs for treating Hodgkin's disease but has only minimal effects against acute leukemia; VCR, on the other hand, is a valuable drug in the treatment of acute leukemia, particularly in children, and is also effective against certain lymphomas and neuroblastomas (Hooker and Bogdanich, 2008).

Also, the equilibrium geometry, various bonding features, and harmonic vibrational wavenumbers and NMR analysis have been investigated with the help of density functional theory (DFT) calculations (Mollaamin et al., 2011; Monajjemi et al., 2010).

But we tried to check the stability of the molecules by information obtained from computational methods and modeling. In computational methods you will be able that check in very small dimensions and this gives us the opportunity to examine the chemical properties of the individual atoms.

However, the vinblastine and vincristine compounds have displayed different spectrum by GIAO been approximations, which appears the results of the determination of the number of active sites in vinblastine and vincristine using the DFT and HF methods with STO-3G, 3-21G,6-31G, 6-31G*, 6-31G** basis sets. These simulations provide an atomistic analysis of the vinblastine and vincristine compounds strategy and their implications for further investigations of microtubule.

Theoretical Background

The chemical shift refers to the phenomenon which associated with the secondary magnetic field created by the induced motions of the electrons that surrounding the nuclei when in the presence of an applied magnetic field. The energy of a magnetic moment μ , in a magnetic field, **B**, is as follow:

$E = -\mu. (1 - \sigma) B$

where the shielding σ , is the differential resonance shift due to the induced motion of the electrons. The chemical shielding is characterized by a real three-by-three Cartesian matrix, which can be decomposed into a single scalar term, three anti symmetric pseudo vector components, and five components corresponding to a symmetric tensor (Facelli, 2002). Only the single scalar and the five symmetric tensor elements can be observed in the normal NMR spectra of the solids. For brevity, these six values are usually referred to as the shielding tensor:

$$\sigma_{xx}\sigma_{xy}\sigma_{xz}$$

$$\sigma_{yx}\sigma_{yy}\sigma_{yz}$$

$$\sigma_{zx}\sigma_{zy}\sigma_{zz}$$

That can be obtained by averaging the off-diagonal values of the complete tensor (Sefzic and Turco, 2005).

The chemical shielding tensor is commonly referred to the chemical shift anisotropy (CSA) tensor according to the possession of second rank properties. The measurement or calculation of the diagonal components (σ_{xx} , σ_{yy} , σ_{zz}) or (σ_{11} , σ_{22} , σ_{33}) in the principle axis system (PAS) allows the complete description of the CSA tensor [sandia].The CSA tensor can also be described by three additional parameters,

a: The isotropic value (or trace portion of the CSA tensor) $\sigma_{_{\rm iso}}$, of the shielding tensor which is defined as

 $\sigma_{iso} = 0.33(\sigma_{11} + \sigma_{22} + \sigma_{33})$ **b:** The anisotropy ($\Delta\sigma$) of the tensor, due to the following expression:

$$\Delta \sigma = \sigma_{33} - 0.5(\sigma_{11} + \sigma_{22})$$

And

c: The shielding tensor asymmetry parameter (η)

$$\eta = \frac{\left|\sigma_{22} - \sigma_{11}\right|}{\left|\sigma_{33} - \sigma_{iso}\right|}$$

computational Methods

We report the results of optimization and nuclear magnetic resonance (NMR) on VLB and VCR. Vinblastine and vincristine theoretically were investigated

Total energy of vinblastine										
basissets methods	sto-3g	3-21g	6-31g	6-31g*	6-31g**					
B3LYP	-1662873.96	-1674885.17	-1683589.764	-1684078	-1684147.388					
BLYP	-1662019.2	-1674190.393	-1682943.514	-1683379	-1683436.779					
HF	-1652943.84	-1664416.991	-1672960.903	-1673677	-1673742.364					
	Total energy of vinblastine Total energy of vinblastine asis sets sto-3g 3-21g 6-31g 6-31g* 6-31g** XP -1662873.96 -1674885.17 -1683589.764 -1684078 -1684147.388 YP -1662019.2 -1674190.393 -1682943.514 -1683379 -1683436.779 F -1652943.84 -1664416.991 -1672960.903 -1673677 -1673742.364 Total energy of vincristine basis sets sto-3g 3-21g 6-31g 6-31g* 6-31g** basis sets sto-3g 3-21g 6-31g 6-31g* 6-31g** basis sets sto-3g 3-21g 6-31g 6-31g* 6-31g** yp -1708561.651 -1720996.651 -1729947.003 -1730540.469 -1730596.861 yp -1707720.927 -1720310.329 -1729310.566 -1729845.889 -1729901.68 F -1698417.326 -1710304.423 -1719195.685 -1719393.609									
basis sets methods	sto-3g	3-21g	6-31g	6-31g*	6-31g**					
B3LYP	-1708561.651	-1720996.651	-1729947.003	-1730540.469	-1730596.861					
BLYP	-1707720.927 BLYP		-1729310.566	-1729845.889	-1729901.68					
HF	-1698417.326	-1710304.423	-1719195.685	-1719939.609	-1720003.403					

Table 1. total energy (Kcal/mol) of vinblastine and vincristine in (B3LYP, BLYP, HF) methods with sto-3g,3-21g,6-31g,6-31g*,6-31g*,6-31g** basis sets.



Figure 1. Energy of vincristine and vinblastine versus basis sets in (B3LYP, BLYP and HF).

by using density functional theory and Hartree–Fock levels of theory with the standard STO-3G, 3-21G,6-31G, 6-31G*, 6-31G**, basis sets employed Gaussian 98 (Frisch et al.,1998). The aim of investigation is comparisons between vincristine and vinblastine in properties of thermodynamics data obtained from NMR chemical shift values.

RESULTS AND DISCUSSION

Energy

To investigate the structural stability, at first we have

optimized the structures of vinblastine and vincristine with hybrid density functional theory (B3LYP,BLYP) and Hartree-Fock (HF) methods with sto-3g,3-21g,6-31g,6-31g*,6-31g** basis sets .Optimized energy for vinblastine and vincristine structures with different methods and basis sets are presented in table 1. By investigation on data We have seen that vincristine is more stable than vinblastine. According to the Figure1, we see that both molecules

with increase the size of basis sets the molecules energy is reduced and is close to its limit value. Also, mentioned trend is correct for all methods (B3LYP, BLYP and HF). We can be seen, in large basis sets (6-31g, 6-31g*, 6-

		Band gap energ	y of vinblastine			
basis sets methods	sto-3g	3-21g	6-31g	6-31g*	6-31g**	
B3LYP	0.15752	0.13093	0.12302	0.14959	0.14969	
BLYP	0.07856	0.06651	0.0593	0.08036	0.08061	
HF 0.46083 0.39312			0.39573	0.39204	0.39179	
		Band gap ener	gy of vincristine			
basis sets methods	sto-3g	3-21g	6-31g	6-31g*	6-31g**	
B3LYP	0.0871	0.08142	0.07354	0.13611	0.13611	
BLYP	0.01417	0.01722	0.01139	0.06991	0.0701	
HF	0.37871	0.33101	0.36905	0.37612	0.37577	

Table 2. band gap energy of vinblastine and vincristine in (B3LYP, BLYP, HF) methods with sto-3g,3-21g,6-31g,6-31g*,6-31g** basis sets.

 Table 3. Dipole moment (Debye) of vinblastine and vincristine in (B3LYP, BLYP, HF) methods with sto-3g,3-21g,6-31g,6-31g*,6-31g** basis sets.

Dipole moment of vinblastine											
basis sets methods	sto-3g	3-21g	6-31g	6-31g*	6-31g**						
B3LYP	6.9863	8.6208	9.0668	7.86	8.026						
BLYP	6.9951	7.6449	7.7057	7.8107	7.8107						
HF	5.9561	8.3616	10.0082	9.047	9.1093						
Dipole moment of vincristine											
basis sets											
methods	sto-3g	3-21g	6-31g	6-31g*	6-31g**						
B3LYP	6.3131	5.1827	5.9815	7.9861	7.9601						
BLYP	6.4239	4.5618	5.7558	7.3849	7.4014						
HF	5.3897	8.6665	8.4569	7.6979	7.7282						

31g**) in all methods which energy of molecules are almost identical.

Band Gap energy of the molecules

The LUMO-HOMO band gap is a gap between the LUMO (the lowest unoccupied molecular orbital) and HOMO (the highest occupied molecular orbital).

It has been shown the band gap energy in all methods and basis sets in two systems and we have resulted that the most stabilized molecule is vincristine in comparison to vinblastine molecule in HF method (Table 2).

Dipole moments of molecules

The central quantity in the physics of dielectrics is the polarization of the material **P**. The polarization **P** is defined as the dipole moment **p** per unit volume. The dipole moment of a system of charges is given by $\mathbf{p} = \sum q_i \mathbf{r}_i$

Where r_i is the position vector of charge q_i . The value of the sum is independent of the choice of the origin of system, provided that the system in neutral.

The two compounds are very similar in structure and apparently also in their primary biological action. Thus the toxicity of VLB and VCR can in many cases be linked to



Figure 2. Dipole moment of vincristine and vinblastine versus basis sets size in (B3LYP, BLYP and HF)



Figure 3. Muliken charge, Anisotropic chemical shift, Asymmetric and Skew parameters versus number of atoms in two-ring segment

disturbances in intracellular microtubular structures resulting from the binding of the alkaloids to a common

target molecule, tubulin, the protein subunits from which microtubules are assembled (Vale , 2003).



Figure. 4. vincristine structure, vinblastine structure and two ring segments of the molecules have been studied and No. of atoms.

Dipole moment of the molecules can be important factor in the binding of the alkaloids to target molecule. Dipole moment of molecule VLB almost in all methods is more than VCR then Inhibition of tubulin polymerization by vinblastine is more than VCR. The inhibition in bothpositive and negative ends of tubules is related to interactions and polarity of drug. Whether the interactions between the drugs are locally determined at the central portion of the b-monomer or globally or at long range, or both, is difficult to ascertain. But we know, if the molecular dipole moment is high, then increase the intermolecular force, therefore at high concentrations, the number of active sites decreased the and pharmacological effects also is reduced. Empirical studies also approved that this topic [25, 26].

According to table 3, dipole moment vinblastine and vincristine in (B3LYP, BLYP, HF) methods with sto-3g,3-

21g,6-31g,6-31g*,6-31g** basis sets have been measured In Figure 2 we can be seen that dipole moments are different with the various methods and basis sets. For example dipole moment of VCR molecule, in both DFT methods (B3LYP,BLYP) are the same but in HF in three small basis set we see that the dipole moment changes is the opposite of DFT methods and in the larger basis sets of HF ,values remained constant and approximately between the values of DFT. In diagram dipole moment of VLB molecule can be seen, dipole moment increases with increasing size of STO-3G to 6-31G and the two basis sets of larger 6-31G* and 6-31G**, Dipole moment decreases and remains constant. In the largest basis set 6-31G**, average values of dipole moment are 8.3153 in VLB and 7.6965 in VCR. Within the Gaussian 98 software suite there is a sub function that uses a calculation method called GIAO (gauge including atomic orbitals) (Jordan and Leslie ,(2004) to calculate isotropic NMR shielding values, from which computed chemical shifts may be derived.

In the standard convention, the principal components of the chemical shift tensor, $(\delta_{11}, \delta_{22}, \delta_{33})$, are labeled according to the IUPAC rules (Jordan and Wilson ,1999). They follow the high frequency-positive order. Thus, δ_{11} corresponds to the direction of lowest shielding, with the highest frequency, while δ_{33} corresponds to the direction of highest shielding, with the lowest frequency.

It is useful to define the span, Ω , and the skew, κ , of a CS tensor. The span is defined as

 $\Omega = \delta_{11} - \delta_{33} = \sigma_{33} - \sigma_{11}$ and indicates the width of the NMR line shape for a nonspinning, stationary, sample. The skew is defined as

$$\frac{3(\delta 22 - \delta iso)}{\Omega} = \frac{3(\sigma iso - \sigma 22)}{\Omega}$$

And provides information on the symmetry of the line shape. For example, κ values of ±1 imply axial symmetry. For nuclear magnetic resonance study of these two molecules, first the same part of the two molecules were removed and then the NMR study was performed on a two-ring segments of the system (the segments are shown in Figure. 3). The NMR shielding constants and correspond-

	2		-			. VI	INBLAST	INE		22		e		2 0		_
	Atomic Name	0	0	N	N		C		C	C	S 0	C	с	с	C	c
	Atomic Number	5	11	14		16	21	S	24	2	9	30	31	33	34	50
	Mulliken atomic charge	es -0.527	73 -0.54	4373 -0.07535		0.083695 0		62306	0.30101	4 -1	0.15839	-0.18483	-0.1864	0.018686	0.296574	-0.0779
B3LYP 6-31G** BLYP 6-31G** HF 6-31G** B3LYP 6-31G** BLYP 6-31G**	Δσ (ppm)	-129.7	55 75.33	645 19.3	19.3001		38.0018 133		125.673	4 1	47.9928	51.65965	118.4682	137.0725	114.3984	66.7453
	ŋ (ppm)	0.4080	32 0.325	279 .0.40	0911	0.5879	02 0.3	86403	0.52931	2 0	.647346	0.276061	0.579383	0.291528	0.765017	0.206707
	k	0.3249	34 0.608	872 0.528472		0.344576 0		43583	0.40009	5 0	.290064	0.662933	0.352533	0.645724	0.187235	0.742156
B3LYP 6-31G** BLYP 6-31G** HF 6-31G** B3LYP 6-31G** BLYP 6-31G** HF 6-31G**	Mulliken atomic charge	es -0.483	78 -0.47	762 -0.0044		0.045022 0		72121	0.32821	5 -1	0.20687	-0.16552	-0.18283	0.040954	0.263044	-0.05554
	Δσ (ppm)	-138.2	27 80.28	28645 23.5453		-14.4024 17		5.0442	124.959	3 1	52.0842	51.19735	109.4646	119.4541	104.5893	68.1544
	n (ppm)	0,3952	34 0.441	.44133 0.687		168 0.749604		97975	0.53323	5 0	.57986	0.357097	0.602539	0.325997	0.627791	0.22125
	k	-0.534	37 0.487	024 0.25	4526	-0.2003	34 0.4	30558	0.39632	1 0	0.352087 (0.574515	0.330983	0.607939	0.307797	0.72526
B3LYP 6-31G** BLYP 6-31G** HF 6-31G** 1 8LYP 6-31G** 1 8LYP 6-31G**	Muliken atomic charge	es -0.676	5 -0.78	064 -0.1	7766	0.1480	03 -0.1	05244	0.37585	3 -1	0.11091	-0.11856	-0.2544	-0.16778	0.433562	-0.0258
	Δσ (ppm)	-128.8	8 83.38	765 23.73695		-20.0899 1		5.8804	155.096	5 1	84.2009	50.9989	124.757	137.2972	135.0151	60.21815
B3LYP 6-31G** 6-31G** HF 6-31G** 8LYP 6-31G** B1YP 6-31G** HF 6-31G**	n (ppm)	0.3595	06 0.139	706 0.44	2823	0.1768	73 0.7	0025	0.75004	8 0	0.637729 0	0.082178	0.655365	0.429098	0.918539	0.116275
6-31G**	k	-0.571	95 0.822	013 0.48	5516	-0.7773	3 0.2	43024	0.19995	9 0	.298761 0	0.893349	0.282844	0.499462	0.062367	0.850753
	1970 -			1.023	001707	10000000	10.0.2	2010	1	100						ACT 247245-1
					1.	V	NCRISTI	NE		_	1.		1.	1.		1
	Atomic Name	0	0	N	C	C		c	C	_	C	C	C	¢	C	C
	Atomic Number	5	6	12	15	1	8	22	26		30	32	33	34	35	52
	Muliken atomic charges	-0.47238	-0.52903	-0.56205	-0.0	6536 0.	062263	0.044	474 0.33	8623	-0.1738	8 -0.16955	0.383023	0.021955	0.292674	-0.08333
B3LYP 6-31G** BLYP 6-31G** HF 6-31G** B3LYP 6-31G** BLYP 6-31G**	Δσ (ppm)	636.8996	-131.639	-164.273	21.69255 24.		4.2524	133.8	436 -12	2.957	150.804	3 127.548	2 -124.715	141.3472	116.1762	67.91265
B3LYP	η (ppm)	0.469009	0.458414	0.301535	0.62	3765 0	77908	9,410	662 0.95	8901	0.67083	9 0.42967	3 0.314834	0.255445	C 34 0.296574 114.3984 0.765017 0.187235 0.263044 104.5893 0.627791 0.437295 0.307797 0.433562 135.0151 0.918539 0.062367 C 35 0.292674 116.1762 5 0.292674 116.1762 5 0.2926674 116.1762 3 0.350496 0.581559 3 0.350496 8 0.427386 136.022 4 0.87949 7 0.093191	0.196521
6-31G**	k	0.459202	-0.4698	-0.63467	0.31	1473 0.	175371	0.518	378 -0.0	0083	0.26900	7 0.498877	-0.62009	0.686133	0.234126	0.754082
	Muliken atomic charges	-0.43953	-0.4866	-0.49153	-0.0	4499 0.	048121	0.087	566 0.31	8918	-0.2041	2 -0.15174	0.340475	0.047403	0.262065	-0.06338
	Δσ (ppm)	622.908	-139.148	-163.057	20.0	.08455 24.369		127.6	673 115	4491	152.959	2 122,403	-121.745	128.8202	106.4833	69.7702
BLYP	(mqq) p	0.485288	0.449281	0.219846	0.79	9816 0.	824663	0.384	625 0.97	7117	0.60243	4 0.429133	5 0.203854	0.27669	0.581559	0.201494
6-31G**	k	0.443044	-0.47899	-0.72688	0.15	8047 0.	137532	0.545	445 0.03	7263	0.33108	0.499424	-0.74549	0.662233	0.350496	0.748248
0.310	Mulliken atomic charges	-0.63865	-0.57796	-0.67913	7913 -0.8248		.17604 0.1587		754 -0.0	7308	0.40582	7 -0-23593	0.570876	-0.16778	0.427386	-0.03331
	Δo (ppm)	644.3693	-129.312	-156.008	22.4	6035 -2	25.1401	139.6	721 -15	1.155	183.026	2 132.43	-134.574	140.6178	136.202	61.6229
HF	η (ppm)	0.392775	0.386734	0.502218	0.19	5911 0.	402106	0.617	074 0.94	9259	0.64060	5 0.497683	0.505146	0.410294	0.87949	0.108184
6-31G**	k	0.536928	-0.54324	-0.4264	0.75	4793 -(0.52723	0.317	598 -0.0	3854	0.29615	6 0.43084	-0.42354	0.518757	0.093191	0.860777

Table 4. NMR shielding constants and corresponding parameters for two-ring segments of the vincristine and vinblastine

ing parameters for two-ring segments of the vincristine and vinblastine are shown in Table 4.

We first consider the B3LYP method and the two molecules were compared in terms of muliken charge. isotropic chemical shift, asymmetric and skew parameters (Figure 3). In the diagrams in Figure 4 can be seen, because there is oxygen No.5 only in vincristine molecule, so, in atom No.33, muliken charge is different from vinblastine and anisotropic chemical shift in atoms with No.33, 12, 26 of vincristine molecule is more negative than vinblastine molecule. Also, we see in Figure. 4 that in general the asymmetry parameter in the atoms of vinblastine molecule is less than vincristine and in atom No.35, two molecules have similar asymmetry parameter but the skew parameter for atoms vincristine is less than vincristine even in the atoms No.6, 12 and 33 is negative.

CONCLUSION

The study of Energy, between the two molecules showed that vincristine structure is more stable from vinblastine and also, calculated energy of molecules with the large basis sets (6-31g, 6-31g*, 6-31g**) in all methods , are

almost identical. In the band gap energy for all methods and basis sets, we saw that vinblastine molecule is more than vincristine molecule. The band gap energy calculation with the method of HF has been the highest values. Dipole moment of molecule VLB almost in all methods is more than VCR then Inhibition of tubulin polymerization by vinblastine is more than VCR. The inhibition in both positive and negative ends of tubules is related to interactions and polarity of drug so, at the initial moment that the concentration of the drug is low, Inhibition effect of VLB is more. In NMR study, we concluded that due to an additional oxygen atom on the ring of the vincristine, charges of atoms and chemical shift of atoms is different from vinblastine.

REFERENCES

Sen A, Maiti M (1994). Interaction of sanguinarine iminium and alkanolamine form with calf thymus DNA. Biochem. Pharmacol. 48, 2097–2102.

Chen WH, Qin Y, Cai Z, Chan CL, Luo GA, Jiang ZH (2005) . Spectrometric studies of cytotoxic protoberberine alkaloids binding to double stranded DNA, Bioorg.Med. Chem. 13 1859–1866.

Qin Y, Pang JY, Chan WH, Cai, Jiang ZH (2006). DNAbinding affinities and binding mode of berberine dimmers, Bioorg. Med. Chem. 14 25–32.

Blask G, Cordell GA (1990). Isolation, structure elucidation and biosynthesis of the bisindole alkaloids of Catharanthus, in: B. Arnold, S. Matthew (Eds.), The Alkaloids: Chemistry and Pharmacology, Academic Press, USA. pp. 1–76.

Blcskei H (2005). Vinblastine-type indole–indoline alkaloids and their derivatives, in: V.G. Kartsev (Ed.), The Chemistry and Biological Activity of Natural Indole Systems, ICFSP, Moscow.

Nakagawa MA, Shimomura Y, Kitagawa Y, Tsurusawa M (2005). Antineoplastic agents for pediatric anaplastic large cell lymphoma: vinblastine is the most effective in vitro, Leuk. Lymphoma 46 (10) 1489–1496.

Lobert SH, Ingram JW, Correia JJ (2006). The thermodynamics of vinca alkaloid-induced tubulin spirals formation, Biophysical chemistry, 126, 50-58.

Lobert SH, Ingram JW, Correia JJ (1999). Additivity of Dilantin and Vinblastine Inhibitory Effects on Microtubule Assembly cancer research, 59, 4816-4822.

Lee JC, Harrison D, Timasheff SN (1975). Interaction of vinblastine with calf brain microtubule protein. Biological Chemistry, 250, (24),9276-9282.

Correia JJ, Lobert S (2001).Physiochemical aspects of tubulin- interacting antimitotic drugs, Current pharmaceutical design, 7, 1213-1228.

Lobert SH, Vulevic B, Coreia JJ (1996). Interaction of vinca alkaloids with tubulin: a comparison of vinblastine, vincristine and vinorelbine, Biochemistry, 35, 6806-6814.

Rai SS, J Wolff (1996).Localization of the vinblastinebinding site on β - tubulin, Biological chemistry, 271(25)14707-14711.

Pearce HL (1990). Medicinal chemistry of bisindole alkaloids from Catharanthus, in: B. Arnold, S. Matthew (Eds.), The Alkaloids: Chemistry and Pharmacology, Academic Press, USA. pp. 145–204.

Kuehne ME, Mark I (1990). Syntheses of vinblastinetype alkaloids, in: B. Arnold, S. Matthew (Eds.), The Alkaloids: Chemistry and Pharmacology, Academic Press, USA. pp. 77–131

Va P, Campbell EL, Robertson WM, Boger DL (2010).Total synthesis and evaluation of a key series of C5-substituted vinblastine derivatives, J. Am. Chem. Soc. 132, 8489–8495.

Sasaki Y, Kato D, Boger DL (2010). Asymmetric total synthesis of vindorosine, vindoline, and key vinblastine analogues, J. Am. Chem. Soc. 132, 13533–13544.

Smith AL ((1997). Oxford dictionary of biochemistry and molecular biology. Oxford Oxfordshire]: Oxford University Press. pp. 43.

Peters GJ, van der Wilt CL, van Moorsel CJ, Kroep JR, Bergman AM, Ackland SP (2000). Basis for effective combination cancer chemotherapy with antimetabolites. Pharmacol. Ther 87 (2–3): 227–53. Radiobiology for the Radiobiologist. Eric Hall. 2006. pp.507.

Mitchison TJ Poleward (1989).microtubule flux in mitotic spindle; evidence from photoactivation of the fluorescence. J Cell Biol ,109:637–652.

Mitchison TJ, Kirschner M (1984).Dynamic instability of microtubule growth. Nature (Lond) 312:237–242.

Margolis RL, Wilson L (1998).Microtubule treadmilling: what goes around comes around. Bioessays,20:830–836. Rodionov VI, Nadezhdina E, Borisy GG (1999) .Centrosomal control of microtubule dynamics. Proc Natl Acad Sci USA ,96:115–120.

Rudner AD and Murray AW (1996). The spindle assembly checkpoint. *Current Biology* **8**:773–780.

Vale RD (2003). The molecular motor toolbox for intracellular transport. Cell 112 (4): 467–80.

Howard J, Hyman AA (2007). "Microtubule polymerases and depolymerases." Curr Opin Cell Biol 19 (1): 31–5.

Jordan MA, Leslie W (2004). Microtubules as a Target for Anticancer Drugs. Nature Reviews Cancer 4 (4): 253– 265.doi:10.1038/nrc1317. PMID 15057285.

Jordan MA, Wilson L (1999).The use and action of drugs in analyzing mitosis. Methods Cell Biol 61:267–295.

<u>Hooker</u> J, <u>Walt Bogdanich</u> W (2008). Tainted Drugs Tied to Maker of Abortion Pill. New York Times.

Mollaamin F, Varmaghani Z, Monajjemi M (2011). Dielectric effect on thermodynamic properties in vinblastine by DFT/Onsager modeling, Physics and

Chemistry of Liquids,49(3), 318–336.

Monajjemi M, Saeid L,Najafi F and Mollaamin F (2010). Physical properties of active site of tubulin–binding as anticancer nanotechnology investigation, Int. J. Phys. Sci.5(10), 1609-1621.

Facelli JC (2002).Encyclopedia of Nuclear Magnetic Resonance; D. M.Grant, R. K. Harris, Eds., London: John Wiley & Sons. 9, 323-333.

Sefzic TH, Turco D (2005). Iuliucci R.J. and Facelli, J.C., J. Phys. Chem. A 109, 1180-1187.

Frisch MJ, Trucks GW, Schlegel HB, Scusera GE, Robb MA, R.Cheeseman J, Zakrzewski VG, Montgomery JA, Stratmann RE Jr,. Burant J.C, Dapprich S, Millam JM, Daniels AD, N.Kudin K, Strain MC, Farkas O, Tomasi J, Barone V, Cossi M, Cammi R, Mennucci B, Pomelli C, Adamo C, Clifford S, Ochterski J, Petersson GA, Cui PY, Ayala Q, Morokuma K, Malick DK, Rabuck AD, Raghavachari K, Foresman JB, Cioslowski J, Ortiz JV, Baboul AG, Stefanov BB, G Liu, Liashenko A, Piskorz P, Komaromi I, Gomperts R, Martin RL,. Fox DJ, Keith T, Al-Laham MA, Peng CY, Nanayakkara A, Gonzalez C, Challacombe M, Gill PMW, Johnson B, Chen W, Wong MW, Andres JL, Gonzalez C, Head-Gordon M, Replogle ES, Pople JA (1998). Gaussian 98, revision A.7; Gaussian, Inc.: Pittsburgh, PA.